REGENERON PHARMACEUTICALS (1REGN.MI) Stock Price & Overview
BIT:1REGN • US75886F1075
Current stock price
The current stock price of 1REGN.MI is 667.6 EUR. Today 1REGN.MI is up by 6.27%. In the past month the price decreased by -33.23%.
1REGN.MI Key Statistics
- Market Cap
- 70.579B
- P/E
- 17.38
- Fwd P/E
- 16.50
- EPS (TTM)
- 38.41
- Dividend Yield
- 0.51%
1REGN.MI Stock Performance
1REGN.MI Stock Chart
1REGN.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1REGN.MI.
1REGN.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 7 / 10 to 1REGN.MI. Both the health and profitability get an excellent rating, making 1REGN.MI a very profitable company, without any liquidiy or solvency issues.
1REGN.MI Earnings
On January 30, 2026 1REGN.MI reported an EPS of 11.44 and a revenue of 3.88B. The company beat EPS expectations (5.66% surprise) and beat revenue expectations (0.21% surprise).
1REGN.MI Forecast & Estimates
36 analysts have analysed 1REGN.MI and the average price target is 726.78 EUR. This implies a price increase of 8.87% is expected in the next year compared to the current price of 667.6.
For the next year, analysts expect an EPS growth of 5.35% and a revenue growth 10.55% for 1REGN.MI
1REGN.MI Groups
Sector & Classification
1REGN.MI Financial Highlights
Over the last trailing twelve months 1REGN.MI reported a non-GAAP Earnings per Share(EPS) of 38.41. The EPS decreased by -2.76% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 31.41% | ||
| ROA | 11.11% | ||
| ROE | 14.41% | ||
| Debt/Equity | 0.09 |
1REGN.MI Ownership
1REGN.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 28.71 | 42.625B | ||
| 1AE | ARGENX SE | 28.77 | 42.6B | ||
| 22UA | BIONTECH SE-ADR | N/A | 23.126B | ||
| ABVX | ABIVAX SA | N/A | 7.766B | ||
| 2X1 | ABIVAX SA | N/A | 7.747B | ||
| GLPG | GALAPAGOS NV | N/A | 1.629B | ||
| GXE | GALAPAGOS NV | N/A | 1.628B | ||
| NANO | NANOBIOTIX | N/A | 1.392B | ||
| PHARM | PHARMING GROUP NV | 46.9 | 1.025B | ||
| PHGN | PHARMING GROUP NV | 47.13 | 1.021B | ||
| 6IV | INVENTIVA SA | N/A | 990.777M | ||
| IVA | INVENTIVA SA | N/A | 934.695M | ||
| DBV | DBV TECHNOLOGIES SA | N/A | 932.473M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1REGN.MI
Company Profile
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
Company Info
IPO: 1991-04-02
REGENERON PHARMACEUTICALS
777 Old Saw Mill River Road
Tarrytown NEW YORK US
Employees: 15410
Phone: 17813705000
REGENERON PHARMACEUTICALS / 1REGN.MI FAQ
Can you describe the business of REGENERON PHARMACEUTICALS?
Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. The company is headquartered in Tarrytown, New York and currently employs 15,410 full-time employees. The firm invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The firm is accelerating drug development using its proprietary technologies, such as VelociSuite, which produces optimized fully human antibodies and new classes of bispecific antibodies. VelociSuite consists of VelocImmune, VelociGene, VelociMouse, VelociMab, Veloci-Bi, VelociT, VelociHum, and other related technologies. Its marketed products include EYLEA (aflibercept); Dupixent (dupilumab); Libtayo (cemiplimab); Ordspono (odronextamab); Kevzara (sarilumab); Itepekimab; Linvoseltamab, and others.
What is the stock price of REGENERON PHARMACEUTICALS today?
The current stock price of 1REGN.MI is 667.6 EUR. The price increased by 6.27% in the last trading session.
Does REGENERON PHARMACEUTICALS pay dividends?
REGENERON PHARMACEUTICALS (1REGN.MI) has a dividend yield of 0.51%. The yearly dividend amount is currently 2.98.
How is the ChartMill rating for REGENERON PHARMACEUTICALS?
1REGN.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 7 out of 10.
Can you provide the number of employees for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (1REGN.MI) currently has 15410 employees.
Can you provide the market cap for REGENERON PHARMACEUTICALS?
REGENERON PHARMACEUTICALS (1REGN.MI) has a market capitalization of 70.58B EUR. This makes 1REGN.MI a Large Cap stock.